Grant Life Sciences (GLIF.OB) Concludes Licensing Of Point-Of-Care -POC- Diagnostic Platform From AccuDx Corp.
10/19/2005 5:13:00 PM
Grant Life Sciences (OTC Bulletin Board: GLIF) announced today that it has signed a licensing agreement with AccuDx Corp., a biotechnology company based in La Jolla, Calif., founded by Ravi Pottahil, Ph.D., one of the world's leading authorities in the field of HIV/AIDS diagnostics and therapeutics.
Under the agreement, Grant Life Sciences now controls the exclusive rights to AccuDx's rapid tests for HIV-1, HIV-2, and Dengue Fever, as well as AccuDx's proprietary colloidal gold reagent. In addition, Grant Life Sciences has the right to manufacture these products in AccuDx's `maquiladora'-modeled contract manufacturing facility in Tijuana, Mexico. This facility is registered with the FDA and is ISO 9002-certified. Financial terms of the agreement were not disclosed.
comments powered by